- Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid LeukemiaZha, Jie; Wang, Ying; Li, Zhenling; Lin, Zhijuan; Cai, Yun; Gong, Tiejun; Md, Wei Yang; Xie, Siting; Huang, Zhenqi; Shi, Pengcheng; Fu, Lin; Wang, Jinghua; Fu, Xiangjun; Feng, Xianqi; Su, Liping; Luo, Jianmin; Yang, Lin; Chen, Biyun; Xie, Ying; Zhu, Yu; Du, Xin; Jiang, Yirong; Li, Zhifeng; Xu, Bing65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.被引 1
- Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid LeukemiaZha, Jie; Zhou, Hui; Zhong, Mengya; Wang, Ying; Du, Xin; Gong, Tiejun; Lin, Zhijuan; Cai, Yun; Xie, Siting; Xie, Chendi; Feng, XianQi; Huang, ZhenQi; Su, Liping; Luo, Jianmin; Yang, Lin; Li, Zhenling; Chen, Bi-yun; Xie, Ying; Zhu, Yu; Shi, Pengcheng; Li, Zhifeng; Jiang, Yirong; Xu, Bing64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 2
- Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid LeukemiaYu, Guopan; Yin, Zhao; Jin, Hua; Yu, Sijian; Li, Yuhua; Nie, Danian; Guo, Ziwen; Sun, Zhiqiang; Meng, Qingxiang; Zhao, Weihua; Lin, Dongjun; Xu, Na; Zhang, Yu64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 3
会议论文
Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia
2被引6阅读
